Holen Sie sich die Stockscreener-App
1.13
0.00%
0.00
Citius Oncology Inc Aktie (CTOR) Neueste Nachrichten
Citius Oncology closes $18 million in offerings to support LYMPHIR launch - Investing.com Nigeria
Citius Oncology Raises $18M Through Direct Offering - TipRanks
Citius Oncology closes $18 million in offerings to support LYMPHIR launch By Investing.com - Investing.com South Africa
Citius Oncology Announces Closing of $18 Million Concurrent Registered Direct Offering and Private Placement Priced At-The-Market Under Nasdaq Rules - Benzinga
Citius Oncology (NASDAQ:CTOR) Shares Up 6.4%What's Next? - MarketBeat
Citius Oncology raises $18 million to support cancer therapy launch By Investing.com - Investing.com Canada
Citius Oncology added to the Russell Microcap Index - MSN
Citius Oncology shares sink after announcing $18M fundraising deal - MSN
Citius Oncology raises $18 million to support cancer therapy launch - Investing.com
Citius Oncology stock tumbles after $18M capital raise By Investing.com - Investing.com South Africa
Citius Oncology stock tumbles after $18M capital raise - Investing.com
Citius Oncology announces $18 million concurrent registered direct offering and private placement priced at-the-market under Nasdaq rules - marketscreener.com
Citius Oncology Announces $18 Million Concurrent Registered Direct Offering and Private Placement Priced At-The-Market Under Nasdaq Rules - Barchart.com
Citius Oncology, Inc. announced that it expects to receive $16.6 million in funding - marketscreener.com
What drives Citius Oncology Inc stock priceStock Price Divergence & Calculate Profit Targets With AI Accuracy - earlytimes.in
Is Citius Oncology Inc a good long term investmentLow Beta Stocks & Free Rapid Profit Acceleration - earlytimes.in
Citius Oncology Launches Lymphir In US For Skin Cancer - MSN
Citius Oncology expands lymphir distribution to Turkey, Middle East By Investing.com - Investing.com Nigeria
Is Citius Oncology Inc. stock a top pick in earnings season2025 Dividend Review & Weekly Top Gainers Alerts - Newser
Citius Oncology Expands LYMPHIR™ Distribution to Turkey and Middle East Countries Through Exclusive Agreement with Er-Kim - The Malaysian Reserve
Citius Oncology Expands LYMPHIR™ Distribution to Turkey and Midd - GuruFocus
Citius Oncology expands lymphir distribution to Turkey, Middle East - Investing.com
Citius Oncology expands Lymphir distribution to Turkey and Middle East countries - marketscreener.com
Citius Oncology Expands Lymphir Distribution To Turkey And Middle East Countries - TradingView — Track All Markets
What Wall Street predicts for Citius Oncology Inc. stock priceStop Loss & Growth Focused Stock Pick Reports - Newser
Citius Oncology launches Lymphir treatment for rare lymphoma - NJBIZ
Citius Oncology enters distribution services agreement with Cardinal Health - MSN
Does Citius Oncology Inc (CTOR) offer a good opportunity for investors? - Setenews
Citius Oncology Announces U.S. Commercial Launch of LYMPHIR, a Novel Cancer Immunotherapy for Cutaneous T-Cell Lymphoma (CTCL) - marketscreener.com
Citius Oncology (CTOR) Stock Analysis Report | Financials & Insights - Benzinga
Citius launches Lymphir in USA for relapsed or refractory CTCL - The Pharma Letter
Citius Oncology Launches LYMPHIR, The First CTCL Systemic Therapy In Over 7 Years - Nasdaq
Citius Pharmaceuticals Launches LYMPHIR for T-Cell Lymphoma - MSN
Will Citius Oncology Inc. stock continue upward momentumJuly 2025 Market Mood & Target Return Focused Picks - Newser
Citius Oncology Announces U.S. Commercial Launch of LYMPHIRtm, a Novel Cancer Immunotherapy for Cutaneous T-Cell Lymphoma (CTCL) - Lelezard
CTORCitius Oncology, Inc. Latest Stock News & Market Updates - Stock Titan
How Citius Oncology Inc. stock performs in weak economyWeekly Earnings Recap & Low Risk High Reward Ideas - Newser
Citius Oncology Launches LYMPHIR for Cutaneous T-Cell Lymphoma - TipRanks
Citius Oncology, Inc. Announces U.S. Launch of LYMPHIR for CTCL - TradingView — Track All Markets
Citius Oncology : Amendment to Statement of Changes in Beneficial Ownership (Form 4/A) - marketscreener.com
Citius Oncology announces U.S. commercial launch of Lymphir for cutaneous T-cell lymphoma - marketscreener.com
Citius Oncology stock soars after commercial launch of LYMPHIR therapy By Investing.com - Investing.com South Africa
Citius Oncology stock soars after commercial launch of LYMPHIR therapy - Investing.com
Citius Oncology rises after U.S. launch of Lymphir as a cancer treatment - Seeking Alpha
Citius Oncology Announces U.S. Commercial Launch of LYMPHIR™, a - GuruFocus
Citius Oncology Launches Cancer Drug Lymphir in the US - marketscreener.com
Citius Oncology launches lymphir for cutaneous T-cell lymphoma By Investing.com - Investing.com South Africa
1.48%
0.09%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):